Market Brief — October 22, 2026

US equities sold off as renewed AI financing worries hit mega-cap tech, with the S&P 500 (SPX) down 1.2%, the Nasdaq Composite (^IXIC) down 2.6% and the Dow (DJIA) little changed with a gain of less than 0.1%. European markets weakened as sovereign-yield concerns persisted, leaving France's CAC 40 (FRA40) down 1.4%, Germany's DAX (DAX) off 1.1% and the FTSE 100 (UKX) lower by 0.3%. In Asia, China's Shanghai Composite (000001.SS) ended flat with a 0.0% move on the day.

Euro-area sovereign risk returned to focus as France's 10-year OAT yield reached about 5.14% and the OAT–Bund spread widened toward 174–178 basis points, with wider spreads across Belgium, Italy, Spain and Greece contributing to pressure on the CAC 40 (FRA40) and DAX (DAX). In the UK, the FTSE 100 (UKX) fell around 0.5% as Barclays' Q3 profit miss and a roughly 5.2% drop in precious-metal miners offset strength in energy stocks supported by Brent above $111–$112 per barrel. Investors also monitored Japan's September inflation release, with calendar entries showing forecasts between 1.8% and 2.3% YoY versus 1.9% previously, while credit data cited high-yield spreads near 332–333 bps and investment-grade spreads around 86 bps.

AI financing worries hit mega-cap tech and chip stocks, sending the Nasdaq Composite (^IXIC) down 2.58% to 26,008.86 and the S&P 500 (SPX) down 1.19% to 7,664.77. Meta Platforms' (META) shares fell more than 6% after it announced a new non-voting Class C share class, guided 2026 capex to $135–$145 billion, reported a Q3 free-cash-flow deficit of $2.12 billion and disclosed about $825 billion of future lease and contract commitments as its five-year CDS reached record levels near 115–119 basis points, while Advanced Micro Devices dropped over 8%, Micron about 6% and Nvidia roughly 4%. Biotech volatility rose after an apparent embargo breach revealed Phase 3 melanoma data for Moderna (MRNA) and Merck's intismeran plus Keytruda showing a 42% reduction in recurrence or death and two-year disease-free survival of 82.2% versus 70.0% for Keytruda alone, sending Moderna as much as 25% lower intraday with a trading halt, while P&G (PG) gained roughly 5%–6% on Q1 organic sales growth of 4.0% and $2.00 core EPS despite flagging a $1.9 billion FY27 cost headwind tied to $100 Brent oil. H.I.G. Capital announced it will acquire a majority stake in L4A, while Sequoia Financial Group agreed to buy Colorado wealth manager Quish and Redesign Health and ARC Global said they will merge to help health systems innovate from within. Additional deal flow included Real Diagnostics' acquisition of SimplyTest, Forte Technologies' purchase of Business Cyber Security Solutions, PRC-Saltillo's acquisition of Ner Chat, Koliway's acquisition of Millhouse Logistics, Critical Metals Corp.'s planned merger with European Lithium, Nightfood Holdings' purchase of CoWoS automated optical inspection technology and Eagle Creative's $20 million offer to acquire RMS Titanic, Inc.